Current Issue: 2026 , 41 , Number 2
| Editor : | Müge AKMANSU |
| Frequency: | 4 issues / year |
| ISSN: | PISSN: 1300-7467 / EISSN: 2717-8978 |
TURKISH JOURNAL OF ONCOLOGY
Dosimetric Comparison of AcurosTM BV with AAPM TG43 Dose Calculation Formalism in Cervix High-Dose-Rate Brachytherapy with Titanium Fletcher Style Tandem and Ovoid Applicator.
Dosimetric Comparison of Helical Tomotherapy and VMAT For Comprehensive Chest Wall and Nodal Irradiation in Left-Sided Breast Cancer Patients.
Age-Based Comparison of Treatment Outcomes and Prognostic Factors in Women with Breast Cancer Receiving Adjuvant Radiotherapy.
Can Radiotherapy Affect Routine Biochemical Parameters? Analytical Stability of Serum Control Materials under Therapeutic Photon Exposure.
Hybrid Planning Technique for Pediatric Craniospinal Irradiation with an O-ring Linac.
The Dosimetric Analysis and Clinical Outcomes of Contiguous Vertebrae Stereotactic Body Radiotherapy in Oligometastatic Patients.
Endoluminal HDR Brachytherapy and Contact X-Ray Therapy in Rectal Cancer: A Narrative Review with an Illustrative Case of Residual Disease After Neoadjuvant Chemoradiotherapy.
First line PD-1 inhibitor, Serplulimab Plus Chemoradiotheraphy for Extensive Stage Thymic Carcinoma: A Case Report.
Dosimetric Comparison of Helical Tomotherapy and VMAT For Comprehensive Chest Wall and Nodal Irradiation in Left-Sided Breast Cancer Patients.
Age-Based Comparison of Treatment Outcomes and Prognostic Factors in Women with Breast Cancer Receiving Adjuvant Radiotherapy.
Can Radiotherapy Affect Routine Biochemical Parameters? Analytical Stability of Serum Control Materials under Therapeutic Photon Exposure.
Hybrid Planning Technique for Pediatric Craniospinal Irradiation with an O-ring Linac.
The Dosimetric Analysis and Clinical Outcomes of Contiguous Vertebrae Stereotactic Body Radiotherapy in Oligometastatic Patients.
Endoluminal HDR Brachytherapy and Contact X-Ray Therapy in Rectal Cancer: A Narrative Review with an Illustrative Case of Residual Disease After Neoadjuvant Chemoradiotherapy.
First line PD-1 inhibitor, Serplulimab Plus Chemoradiotheraphy for Extensive Stage Thymic Carcinoma: A Case Report.













